10/01/2026 | Press release | Distributed by Public on 10/01/2026 14:55
TABLE OF CONTENTS
|
☒
|
Preliminary Proxy Statement
|
|
☐
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
☐
|
Definitive Proxy Statement
|
|
☐
|
Definitive Additional Materials
|
|
☐
|
Soliciting Material under §240.14a-12
|
|
|
|
Adagio Medical Holdings, Inc.
|
|
(Name of Registrant as Specified in Its Charter)
|
|
(Name of Person(s) Filing Proxy Statement if other than the Registrant)
|
|
|
|
☒
|
No fee required
|
|
☐
|
Fee paid previously with preliminary materials
|
|
☐
|
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
|
TABLE OF CONTENTS
|
|
|
|
|
|
By Order of the Board of Directors.
|
|
|
|
|
|
|
||
|
|
|
||
|
Deborah Kaster
Chief Financial Officer and Chief Business Officer
Laguna Hills, CA
October [ ], 2026 |
|
||
|
|
|
TABLE OF CONTENTS
|
|
|
|
|
|
|
|
Page
|
|
|
PROXY STATEMENT
|
|
|
1
|
|
PROPOSAL NO. 1 - APPROVAL OF A SERIES OF ALTERNATE AMENDMENTS TO OUR AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT OF OUR COMMON STOCK
|
|
|
6
|
|
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
|
|
|
14
|
|
OTHER INFORMATION FOR STOCKHOLDERS
|
|
|
16
|
|
APPENDIX A - CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
|
|
|
A-1
|
|
|
|
|
|
TABLE OF CONTENTS
TABLE OF CONTENTS
|
•
|
Proposal No. 1 - To approve a series of alternate amendments to the Company's Amended and Restated Certificate of Incorporation to effect, at the option of the Board, a reverse stock split of our common stock at a ratio in the range of 1-for-10 to 1-for-500, inclusive (the "Reverse Stock Split"), with such ratio to be determined by the Board in its sole discretion.
|
TABLE OF CONTENTS
|
|
|
|
|
|
|
|
|
|
|
|
By Internet
|
|
|
By
Telephone
|
|
|
By Mail
|
|
|
During the Meeting
|
|
You may vote your shares from any location in the world at www.proxyvote.com (you will need the control number printed on your proxy card)
|
|
|
You may vote your shares by calling 1-800-690-6903 and following the instructions on your proxy card.
|
|
|
If you received a proxy card by mail, you may vote by completing, dating and signing the proxy card and promptly mailing it in the postage-paid envelope provided.
|
|
|
To vote at the meeting, visit www.virtualshareholdermeeting.com/ADGM2026SM (you will need the control number printed on your proxy registration confirmation email)
|
|
|
|
|
|
|
|
|
|
|
|
TABLE OF CONTENTS
|
•
|
You may submit another properly completed proxy card with a later date.
|
|
•
|
You may grant a subsequent proxy by telephone or through the internet.
|
|
•
|
You may send a timely written notice that you are revoking your proxy to Adagio's Corporate Secretary at 26051 Merit Circle, Suite 102, Laguna Hills, CA, 92653. Such notice will be considered timely if it is received at the indicated address by the close of business on the business day one week preceding the date of the Special Meeting.
|
|
•
|
You may attend the Special Meeting and vote online. Simply attending the Special Meeting will not, by itself, revoke your proxy.
|
TABLE OF CONTENTS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proposal
|
|
|
Page
Number
|
|
|
Vote Required for
Approval
|
|
|
Voting Options
|
|
|
Effect of Votes
Withheld/
Abstentions,
As Applicable
|
|
|
Effect of Broker
Non-Votes
|
|
|
|
Proposal No. 1: Reverse Stock Split(1)
|
|
|
6
|
|
|
FOR votes from the holders of a majority of the voting power of the shares present in person or represented by proxy at the meeting and entitled to vote
|
|
|
FOR, AGAINST or ABSTAIN
|
|
|
No effect
|
|
|
Not applicable
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
This proposal is considered to be a "routine" matter under NYSE rules. Accordingly, if you hold your shares in street name and do not provide voting instructions to your broker, bank or other agent that holds your shares, your broker, bank or other agent has discretionary authority to vote your shares on this proposal.
|
TABLE OF CONTENTS
|
•
|
effect a reverse stock split, or the Reverse Stock Split, of all of the outstanding shares of our common stock at a ratio of between 1-for-10 and 1-for-500, inclusive.
|
TABLE OF CONTENTS
TABLE OF CONTENTS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reverse Stock Split Ratio
|
|
|
-
|
|
|
10:1
|
|
|
100;1
|
|
|
200:1
|
|
|
300;1
|
|
|
400;1
|
|
|
500:1
|
|
Number of shares of Common Stock Issued and Outstanding
|
|
|
[ ]
|
|
|
[ ]
|
|
|
[ ]
|
|
|
[ ]
|
|
|
[ ]
|
|
|
[ ]
|
|
|
[ ]
|
|
Number of Shares of Common Stock Reserved for Future Issuance
|
|
|
[ ]
|
|
|
[ ]
|
|
|
[ ]
|
|
|
[ ]
|
|
|
[ ]
|
|
|
[ ]
|
|
|
[ ]
|
|
Number of Shares of Common Stock Authorized but Unissued and Unreserved
|
|
|
[ ]
|
|
|
[ ]
|
|
|
[ ]
|
|
|
[ ]
|
|
|
[ ]
|
|
|
[ ]
|
|
|
[ ]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
•
|
each ten to five hundred shares of our common stock owned by a stockholder (depending on the Reverse Stock Split ratio selected by the Board), will be combined into one new share of our common stock;
|
|
•
|
no fractional shares of common stock will be issued in connection with any Reverse Stock Split; instead, holders of common stock who would otherwise receive a fractional share of common stock pursuant to the Reverse Stock Split will receive cash in lieu of the fractional share as explained more fully below;
|
|
•
|
based upon the Reverse Stock Split ratio selected by the Board, proportionate adjustments will be made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all then outstanding stock options, restricted stock units and warrants, which will result in a proportional decrease in the number of shares of our common stock reserved for issuance upon exercise or vesting of such stock options, restricted stock units and warrants, and, in the case of stock options and warrants, a proportional increase in the exercise price of all such stock options and warrants; and
|
|
•
|
the number of shares then reserved for issuance under our equity compensation plans will be reduced proportionately based upon the Reverse Stock Split ratio selected by the Board (as described below).
|
TABLE OF CONTENTS
TABLE OF CONTENTS
|
•
|
The reduced number of shares of our common stock resulting from a Reverse Stock Split could adversely affect the liquidity of our common stock.
|
|
•
|
The Reverse Stock Split could result in a significant devaluation of our market capitalization and the trading price of our common stock, on an actual or an as-adjusted basis, based on the experience of other companies that have effected reverse stock splits.
|
|
•
|
The Reverse Stock Split may leave certain stockholders with one or more "odd lots," which are stock holdings in amounts of less than 100 shares of our common stock. These odd lots may be more difficult to sell
|
TABLE OF CONTENTS
|
•
|
There can be no assurance that the market price per new share of our common stock after the Reverse Stock Split will increase in proportion to the reduction in the number of old shares of our common stock outstanding before the Reverse Stock Split. For example, based on the closing market price of our common stock on [ ], 2026 of $[ ] per share of common stock, if the stockholders approve this proposal and the Board selects and implements a Reverse Stock Split ratio of 1-for-100, there can be no assurance that the post-split market price of our common stock would be $[ ] per share or greater. Accordingly, the total market capitalization of our common stock after the proposed Reverse Stock Split may be lower than the total market capitalization before the proposed Reverse Stock Split and, in the future, the market price of our common stock following the Reverse Stock Split may not exceed or remain higher than the market price prior to the proposed Reverse Stock Split.
|
|
•
|
While the Board believes that a higher stock price may help generate investor interest, there can be no assurance that the Reverse Stock Split will result in a per share price that will attract institutional investors or investment funds or that such share price will satisfy the investing guidelines of institutional investors or investment funds. As a result, the trading liquidity of our common stock may not necessarily improve.
|
|
•
|
If the Reverse Stock Split is effected and the market price of our common stock declines, the percentage decline may be greater than would occur in the absence of a Reverse Stock Split. The market price of our common stock will, however, also be based on our performance and other factors, which are unrelated to the number of shares outstanding.
|
TABLE OF CONTENTS
|
•
|
an individual who is a citizen or resident of the United States or treated as a U.S. citizen or resident for U.S. federal income tax purposes;
|
|
•
|
a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state thereof, or the District of Columbia;
|
|
•
|
an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or
|
|
•
|
a trust if (i) a U.S. court can exercise primary supervision over the trust's administration and one or more "United States persons" (within the meaning of Section 7701(a)(30) of the Code) are authorized or have the authority to control all substantial decisions of the trust or (ii) it has a valid election in effect under applicable Treasury Regulations to be treated as a United States person for U.S. federal income tax purposes.
|
TABLE OF CONTENTS
TABLE OF CONTENTS
|
•
|
each director and nominee for director;
|
|
•
|
each of the Company's named executive officers;
|
|
•
|
each person known by the Company to be the beneficial owner of more than 5% of the Company's outstanding shares Common Stock; and
|
|
•
|
all current executive officers and directors of the Company as a group
|
|
|
|
|
|
|
|
|
|
Name and Address of Beneficial Owners(1)
|
|
|
Number of
Shares
|
|
|
%
|
|
Current Executive Officers and Directors
|
|
|
|
|
||
|
James L. Cox(2)
|
|
|
184,698
|
|
|
[ ]
|
|
Deborah Kaster(3)
|
|
|
436,009
|
|
|
[ ]
|
|
Sandra Gardiner(4)
|
|
|
80,000
|
|
|
[ ]
|
|
Keyvan Mirsaeedi-Farahani(5)
|
|
|
80,000
|
|
|
[ ]
|
|
Orly Mishan(6)
|
|
|
266,666
|
|
|
[ ]
|
|
Timothy Moran(7)
|
|
|
80,000
|
|
|
[ ]
|
|
Sean Salmon(8)
|
|
|
37,500
|
|
|
[ ]
|
|
Todd Usen(9)
|
|
|
1,079,650
|
|
|
[ ]
|
|
All current directors and executive officers as a group (eight individuals)(10)
|
|
|
2,244,523
|
|
|
[ ]
|
|
Former Executive Officers
|
|
|
|
|
||
|
Hakon Bergheim
|
|
|
7,539
|
|
|
[ ]
|
|
Five Percent Holders
|
|
|
|
|
||
|
Entities affiliated with Perceptive Advisors LLC(11)
|
|
|
15,321,655
|
|
|
[ ]
|
|
Alyeska Master Fund, L.P.(12)
|
|
|
2,336,384
|
|
|
[ ]
|
|
Entities affiliated with RA Capital Management, L.P.(13)
|
|
|
1,200,000
|
|
|
[ ]
|
|
Entities affiliated with Sio Capital Management, LLC(14)
|
|
|
698,989
|
|
|
[ ]
|
|
Entities affiliated with ADAR1 Capital Management LLC(15)
|
|
|
1,205,447
|
|
|
[ ]
|
|
Entities affiliated with Adage Capital Management, L.P.(16)
|
|
|
1,258,501
|
|
|
[ ]
|
|
|
|
|
|
|
|
|
|
*
|
Less than 1%
|
|
(1)
|
This table is based upon information supplied by officers, directors and principal stockholders and Schedules 13D and 13G filed with the SEC. Unless otherwise indicated in the footnotes to this table and subject to community property laws where applicable, the Company believes that each of the stockholders named in this table has sole voting and investment power with respect to the shares indicated as beneficially owned. The business address of each beneficial owner unless otherwise stated is 26051 Merit Cir #102, Laguna Hills, CA 92653.
|
|
(2)
|
Consists of (a) 36,698 shares of common stock and (b) 148,000 shares of common stock issuable upon exercise of options exercisable within 60 days of September 30, 2026.
|
|
(3)
|
Consists of (a) 15,000 shares of common stock and (b) 421,009 shares of common stock issuable upon exercise of options exercisable within 60 days of September 30, 2026.
|
|
(4)`
|
Consists of 80,000 shares of common stock issuable upon exercise of options exercisable within 60 days of September 30, 2026.
|
TABLE OF CONTENTS
|
(5)
|
Consists of 80,000 shares of common stock issuable upon exercise of options exercisable within 60 days of September 30, 2026.
|
|
(6)
|
Consists of 266,666 shares of common stock issuable upon exercise of options exercisable within 60 days of September 30, 2026.
|
|
(7)
|
Consists of 80,000 shares of common stock issuable upon exercise of options exercisable within 60 days of September 30, 2026.
|
|
(8)
|
Consists of 37,500 shares of common stock issuable upon exercise of options exercisable within 60 days of September 30, 2026.
|
|
(9)
|
Consists of (a) 207,315 shares of common stock and (b) 872,335 shares of common stock issuable upon exercise of options exercisable within 60 days of September 30, 2026.
|
|
(10)
|
Consists of (a) 259,013 shares of common stock and (b) 1,985,510 shares of common stock issuable upon exercise of options exercisable within 60 days of September 30, 2026.
|
|
(11)
|
Consists of (i) 9,675,684 shares of Common Stock directly held by Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund"), (ii) warrants directly held by the Master Fund exercisable into 5,445,069 shares of Common Stock, and (iii) 200,902 shares of Common Stock directly held by C2 Life Sciences LLC ("C2"). Such amounts do not include shares of common stock issuable upon exercise of pre-funded warrants and warrants that may not be exercised if the aggregate number of shares of common stock beneficially owned by entities affiliated with Master Fund would exceed 9.99% of the total number of shares of our common stock then issued and outstanding after giving effect to such exercise. Perceptive Advisors LLC (the "Advisor") serves as the investment manager of the Master Fund and C2. Joseph Edelman serves as the managing member of the Advisor. Accordingly, the Advisor and Mr. Edelman have voting and investment discretion with respect to, and may be deemed to beneficially own, the shares of Common Stock and warrants held of record by the Master Fund and C2. The Advisor does not directly hold any shares of Common Stock or warrants. The principal business address of each of these persons and entities is 51 Astor Place, 10th Floor, New York, NY 10003.
|
|
(12)
|
Consists of (i) 1,159,615 shares of Common Stock and (ii) Milestone Warrants (as defined below) exercisable into 1,176,769 shares of Common Stock, in each case held by Alyeska Master Fund, L.P. Such amounts do not include shares of common stock issuable upon exercise of warrants that may not be exercised if the aggregate number of shares of common stock beneficially owned by entities affiliated with Alyeska Master Fund, L.P. would exceed 9.99% of the total number of shares of our common stock then issued and outstanding after giving effect to such exercise. Alyeska Investment Group, L.P., the investment manager of Alyeska Master Fund, L.P., has voting and investment control of the shares held by Alyeska Master Fund, L.P. Anand Parekh is the Chief Executive Officer of Alyeska Investment Group, L.P. and may be deemed to be the beneficial owner of such shares. Mr. Parekh, however, disclaims any beneficial ownership of the shares held by Alyeska Master Fund, L.P. The registered address of Alyeska Master Fund, L.P. is at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, South Church Street George Town, Grand Cayman, KY1-1104, Cayman Islands. Alyeska Investment Group, L.P. is located at 77 W. Wacker, Suite 700, Chicago IL 60601.
|
|
(13)
|
Consists of (i) warrants held directly by RA Capital Healthcare Fund, L.P. ("RA Capital Fund") that are exercisable for an aggregate of up to 1,140,000 shares of Common Stock and (ii) warrants held directly by RA Capital Nexus Fund II, L.P. ("Nexus Fund II") that are exercisable for an aggregate of up to 60,000 shares of Common Stock. RA Capital Healthcare Fund GP, LLC is the general partner of RA Capital Fund and RA Capital Nexus Fund II GP, LLC is the general partner of Nexus Fund II. The general partner of RA Capital is RA Capital Management GP, LLC, of which Peter Kolchinsky and Rajeev Shah are the controlling persons. RA Capital serves as investment adviser for each of RA Capital Fund and Nexus Fund II and may be deemed a beneficial owner, for purposes of Section 13(d) of the Act, of any securities of Adagio held by RA Capital Fund or Nexus Fund II. Each of RA Capital Fund and Nexus Fund II has delegated to RA Capital Management, L.P. ("RA Capital") the sole power to vote and the sole power to dispose of all securities held in its portfolio, including the shares of Common Stock reported herein. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. The principal business address of the persons and entities listed above is 200 Berkeley Street, 18th Floor, Boston, MA 02116.
|
|
(14)
|
Consists of 698,989 shares of common stock beneficially owned by Sio Capital Management, LLC ("Sio Management"). Such amount does not include shares of common stock issuable upon exercise of warrants that may not be exercised if the aggregate number of shares of common stock beneficially owned by entities affiliated with Sio Management would exceed 4.99% of the total number of shares of our common stock then issued and outstanding after giving effect to such exercise. Sio Management is the investment manager of Sio Partners, LP ("Sio Partners"), Sio Partners Offshore LTD ("Sio Offshore"), Compass SAV II ("Compass SAV") , and Compass Offshore SAV II PCC Limited ("Compass Offshore"), and Michael Castor is the sole owner and Managing Member of Sio Management. Sio Management and Mr. Castor may be deemed to beneficially own the securities held by Sio Partners, Sio Offshore, Compass SAV, and Compass Offshore. Sio GP LLC is the General Partner of Sio Partners. Each of Sio Capital Management LLC, Sio GP LLC and Michael Castor disclaims beneficial ownership over the securities held of record by stockholders, except to the extent of its or his pecuniary interest therein. The business address of each of the foregoing entities and persons is c/o Sio Capital Management, LLC, 600 Third Avenue, 2nd Floor, New York, NY 10016.
|
|
(15)
|
Consists of (i) 1,054,697 shares of common stock held by ADAR1 Partners, LP ("ADAR1 LP") and (ii) 150,750 shares of common stock held by Spearhead Insurance Solutions IDF, LLC - Series ADAR1 ("Spearhead"). Such amounts do not include shares of common stock issuable upon exercise of warrants that may not be exercised if the aggregate number of shares of common stock beneficially owned by entities affiliated with ADAR1 Capital Management LLC would exceed 4.99% of the total number of shares of our common stock then issued and outstanding after giving effect to such exercise. As the investment manager of ADAR1 LP and as the sub-advisor of Spearhead, ADAR1 Capital Management, LLC, or ADAR1, may be deemed to indirectly beneficially own securities held by ADAR1 LP and Spearhead. Mr. Daniel Schneeberger is the Manager of ADAR1 and may be deemed to indirectly beneficially own securities held by ADAR1 LP and Spearhead. The address of ADAR1 is 3503 Wild Cherry Drive, Building 9, Austin, TX 78738. The address of Spearhead is 3828 Kennett Pike, Suite 202, Greenville, DE 19807.
|
|
(16)
|
Consists of 1,258,501 shares of common stock held by Adage Capital Partners, L.P. ("ACP"). Adage Capital Management, L.P. ("ACM") is the investment manager of ACP. Robert Atchinson is the managing member of Adage Capital Advisors, L.L.C. ("ACA") which is the managing member of Adage Capital Partners GP, L.L.C. ("ACPGP"), and Mr. Atchinson is the managing member of Adage Capital Partners LLC ("ACPLLC"), which is the general partner of ACM. Phillip Gross is the managing member of ACA, which is the managing member of ACPGP, and Mr. Gross is the managing member of ACPLLC, which is general partner of ACM. Both Mr. Atchinson and Mr. Gross disclaim beneficial ownership of any of the shares of Common Stock held by ACM except to the extent of his respective pecuniary interest therein. The address of the foregoing entities is 200 Clarendon St., 52nd Floor, Boston, MA 02116.
|
TABLE OF CONTENTS
TABLE OF CONTENTS
|
|
|
|
|
|
|
|
By Order of the Board of Directors
|
|
|
|
|
||
|
|
|
||
|
|
|
Deborah Kaster
|
|
|
|
|
Chief Financial Officer and Chief Business Officer
|
|
|
|
|
October [ ], 2026
|
|
|
|
|
|
|
TABLE OF CONTENTS
|
1.
|
The name of the corporation is Adagio Medical Holdings, Inc. (the "Corporation").
|
|
2.
|
The Corporation's original Certificate of Incorporation was filed on July 29, 2024 (the "Certificate")
|
|
3.
|
The Corporation's Board of Directors and stockholders, acting in accordance with the provisions of Sections 141 and 242 of the DGCL, adopted resolutions approving the following amendments to the Certificate:
|
|
4.
|
All other provisions of the Certificate will remain in full force and effect.
|
|
1
|
These amendments approve the combination of any whole number of shares of the Company's Common Stock between and including ten (10) and five hundred (500) into one (1) share of the Company's Common Stock. By these amendments, the stockholders would approve each of the alternate amendments proposed by the Company's Board of Directors. If the reverse stock split proposal is approved by stockholders, the Certificate of Amendment filed with the Secretary of State of the State of Delaware will include only that reverse stock split ratio determined by the Company's Board of Directors to be in the best interests of the Company and its stockholders. The other amendments will be abandoned pursuant to Section 242(c) of the General Corporation Law of the State of Delaware. The Company's Board of Directors may also elect not to effect any reverse stock split, in which case all proposed alternate amendments will be abandoned.
|
TABLE OF CONTENTS
|
5.
|
This Certificate of Amendment has been duly adopted in accordance with the provisions of Section 242 of the DGCL.
|
|
6.
|
This amendment to the Certificate of Incorporation shall be effective on and as of as of the effective time of 5:00 p.m., Eastern Time, on [•], 2026.
|
TABLE OF CONTENTS
|
|
|
|
|
|||
|
|
|
Adagio Medical Holdings, Inc.
|
||||
|
|
|
|
|
|||
|
|
|
By:
|
|
|
||
|
|
|
Name:
|
|
|
Todd Usen
|
|
|
|
|
Title:
|
|
|
Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
TABLE OF CONTENTS
TABLE OF CONTENTS